Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$1.09 AUD
Change Today +0.03 / 2.83%
Volume 700.7K
As of 2:10 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

impedimed ltd (IPD) Snapshot

Open
A$1.07
Previous Close
A$1.06
Day High
A$1.09
Day Low
A$1.07
52 Week High
08/6/15 - A$1.25
52 Week Low
09/1/14 - A$0.33
Market Cap
319.7M
Average Volume 10 Days
934.6K
EPS TTM
A$-0.06
Shares Outstanding
293.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPEDIMED LTD (IPD)

Related News

No related news articles were found.

impedimed ltd (IPD) Related Businessweek News

No Related Businessweek News Found

impedimed ltd (IPD) Details

ImpediMed Limited develops, manufactures, and sells bioimpedance and bioimpedance spectroscopy devices, and consumables for clinicians and allied health professionals in Australia, Canada, Mexico, The United States, and internationally. The company operates through Medical, and Test & Measurement segments. The Medical segment offers non-invasive medical devices for the assessment and monitoring of secondary lymphoedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring, and sports medicine and fitness, as well as body composition and hydration. The Test & Measurement segment supplies power precision testing and measuring equipment. The company offers its products through distributors. ImpediMed Limited was founded in 1999 and is based in Pinkenba, Australia.

43 Employees
Last Reported Date: 08/26/15
Founded in 1999

impedimed ltd (IPD) Top Compensated Officers

Chief Executive Officer, President and Managi...
Total Annual Compensation: A$571.1K
Chief Financial Officer
Total Annual Compensation: A$282.2K
Vice President of Global Commercialization
Total Annual Compensation: A$313.4K
Vice President of Product Development, Qualit...
Total Annual Compensation: A$267.7K
Vice President of Regulatory, Clinical Affair...
Total Annual Compensation: A$267.7K
Compensation as of Fiscal Year 2014.

impedimed ltd (IPD) Key Developments

ImpediMed Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015; Provides Earnings Guidance for the Year 2016

ImpediMed Limited reported audited consolidated earnings results for the year ended June 30, 2015. For the year, the company reported revenue of AUD 4.93 million compared to AUD 3.58 million a year ago. Loss from continuing operations before income tax was AUD 14.80 million compared to AUD 7.94 million a year ago. Loss from continuing operations after income tax was AUD 14.80 million compared to AUD 7.94 million a year ago. Net loss for the period was AUD 14.80 million compared to AUD 7.94 million a year ago. Basic and diluted loss per share was AUD 0.06 compared to AUD 0.04 a year ago. Net cash flow s used in operating activities was AUD 10.76 million compared to AUD 6.80 million a year ago. Purchase of property and equipment was AUD 0.132 million compared to AUD 0.032 million a year ago. The Group expects to continue to generate a net loss in financial year 2016 while it focuses on expansion of its position in the US lymphoedema market through continued investment in the sales and marketing initiatives associated with the full commercial launch and the advancement of the five-year multi-centre clinical trial.

ImpediMed Limited Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 10:30 AM

ImpediMed Limited Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 10:30 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

ImpediMed Limited Appoints Richard Carreon as Managing Director

ImpediMed Limited announced the appointment of Mr. Richard Carreon as Managing Director of the company effective 9 May 2015. Mr. Carreon is currently the Chief Executive Officer of the Company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPD:AU A$1.09 AUD +0.03

IPD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPD.
View Industry Companies
 

Industry Analysis

IPD

Industry Average

Valuation IPD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 69.6x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 54.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPEDIMED LTD, please visit www.impedimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.